HC Wainwright Reaffirms “Buy” Rating for Cullinan Therapeutics (NASDAQ:CGEM)

Cullinan Therapeutics (NASDAQ:CGEM)‘s stock had its “buy” rating reiterated by HC Wainwright in a research note issued to investors on Friday, Benzinga reports. They presently have a $35.00 price objective on the stock. HC Wainwright’s target price indicates a potential upside of 115.38% from the company’s current price. HC Wainwright also issued estimates for Cullinan Therapeutics’ Q1 2027 earnings at ($0.95) EPS, Q2 2027 earnings at ($0.96) EPS, Q3 2027 earnings at ($0.98) EPS, Q4 2027 earnings at ($1.00) EPS and FY2027 earnings at ($3.89) EPS.

CGEM has been the topic of several other reports. Wall Street Zen lowered shares of Cullinan Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, September 13th. Wedbush lifted their price target on Cullinan Therapeutics from $39.00 to $42.00 and gave the stock an “outperform” rating in a research note on Thursday, August 13th. TD Cowen raised Cullinan Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cullinan Therapeutics in a research note on Wednesday, July 8th. Finally, BTIG Research reaffirmed a “buy” rating and set a $40.00 price target on shares of Cullinan Therapeutics in a research note on Friday, September 25th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $33.71.

Cullinan Therapeutics Stock Performance

Shares of NASDAQ CGEM opened at $16.25 on Friday. The firm has a market capitalization of $1.05 billion, a P/E ratio of -5.24 and a beta of -0.05. Cullinan Therapeutics has a one year low of $5.71 and a one year high of $23.19. The company’s fifty day moving average is $19.48 and its two-hundred day moving average is $16.78.

Cullinan Therapeutics (NASDAQ:CGEM) last issued its earnings results on Thursday, August 6th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.01). On average, sell-side analysts forecast that Cullinan Therapeutics will post -3.06 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Jennifer Michaelson sold 30,000 shares of the business’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $20.26, for a total value of $607,800.00. Following the completion of the transaction, the insider owned 162,844 shares of the company’s stock, valued at approximately $3,299,219.44. The trade was a 15.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 8.60% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in CGEM. BlackRock Inc. acquired a new position in Cullinan Therapeutics in the 2nd quarter valued at about $95,289,000. Blue Owl Capital Holdings LP acquired a new position in Cullinan Therapeutics in the 2nd quarter valued at about $28,039,000. Boothbay Fund Management LLC acquired a new position in Cullinan Therapeutics in the 4th quarter valued at about $12,803,000. Boone Capital Management LLC acquired a new position in Cullinan Therapeutics in the 2nd quarter valued at about $12,828,000. Finally, Elmind Capital LP acquired a new position in Cullinan Therapeutics in the 2nd quarter valued at about $12,564,900. Institutional investors and hedge funds own 86.31% of the company’s stock.

Cullinan Therapeutics News Roundup

Here are the key news stories impacting Cullinan Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its EPS forecasts across multiple periods, including Q3 2026 to $(0.86) from $(0.90), Q4 2026 to $(0.89) from $(0.93), FY2026 to $(3.45) from $(3.53), and FY2027 to $(1.81) from $(3.89). The revisions suggest the firm expects Cullinan’s losses to narrow more quickly than previously projected. HC Wainwright Has Optimistic Opinion of CGEM Q3 Earnings
• Positive Sentiment: The largest improvement was for Q1 2027, where HC Wainwright now expects a $(0.44) loss per share versus its prior $(0.95) estimate. It also raised Q2 2027 and Q3 2027 forecasts modestly and now projects positive EPS of $0.39 in Q4 2027, indicating a potential path toward profitability.
• Neutral Sentiment: Despite the upgrades, Cullinan is still expected to report significant losses in 2026, with HC Wainwright forecasting $(3.45) EPS for the year versus a consensus estimate of approximately $(3.08). The outlook remains dependent on clinical and commercial progress typical of a biotechnology company.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing innovative medicines for cancer and autoimmune diseases. The company uses a portfolio-based approach to advance targeted therapies and immune-modulating treatments intended to address significant unmet medical needs.

Cullinan’s pipeline includes zovoltamab brengitecan (CLN-978), an investigational CD19-directed T-cell engager being studied in B-cell malignancies and autoimmune conditions, and CLN-619, an investigational antibody designed to target MICA and MICB proteins and stimulate anti-tumor immune responses.